What is Aimovig (erenumab)?
Aimovig (erenumab) is the first drug approved by the FDA to prevent migraines. It blocks a molecule called calcitonin gene-related peptide. This molecule plays a key role in migraine attacks.
It comes in an AutoInjector pen with 70mg/ml or 140mg/ml.
Who is Aimovig (erenumab) for?
Aimovig (erenumab) is for adults who suffer from migraines. It helps those with episodic and chronic migraines. Episodic migraines occur 4 to 14 days a month. Chronic migraines happen 15 or more days a month, with 8 being migraines.
[Please note that approvals in some countries may be for some subtypes and not all migraines].
How does Aimovig (erenumab) work?
Erenumab, the active substance in Aimovig, is a human monoclonal antibody. It blocks the activity of calcitonin gene-related peptide (CGRP). CGRP is involved in migraine attacks.
Studies show that CGRP is released more during migraine attacks. Blocking CGRP and its receptor helps relieve migraine pain. This supports its role in migraines.
Where has Aimovig (erenumab) been approved?
Aimovig (erenumab) was approved for migraine treatment by:
- Food and Drug Administration (FDA), USA, on May 17, 2018
- Therapeutic Goods Administration (TGA), Australia, July 2, 2018
- Swissmedic, Switzerland, July 13, 2018
- European Medical Agency (EMA), European Union, July 26, 2018, for adults with 4 or more migraine days per month
- Health Canada, Canada, August 1, 2018, for adults with 4 or more migraine days per month
- Medsafe, New Zealand, January 16, 2020.
- The Pharmaceuticals and Medical Devices Agency (PMDA), Japan on June 23, 2021
It may also be approved in other regions. If you have questions, contact our support team.
We’ve helped patients from many countries get Aimovig. Most come from:
- United Kingdom (UK)
- Portugal
- Turkey
- Egypt
- Pakistan
- Romania
- South Africa
How is Aimovig (erenumab) taken?
The standard dosage is:
- 70 mg injected subcutaneously (under the skin) once monthly.
- Some patients may need 140 mg, given as two 70 mg injections.
Aimovig (erenumab) is meant for patients to give themselves.
For more details on dosage and administration, see the official prescribing information in our resources section.
Note: Always talk to your doctor for the right dosage for you.
Are there any known side effects or adverse reactions of Aimovig (erenumab)?
Common adverse reactions
The most common side effects of Aimovig (erenumab-aooe) include[2]:
- injection site reactions
- constipation.
Contraindications
Aimovig (erenumab-aooe) should not be used by people with serious allergies to it or its ingredients.
Use in specific populations
Women with migraine might worry about pregnancy and breastfeeding. They fear their baby could be affected by the medicine. There’s no solid data yet on Aimovig’s impact on pregnancy and breastfeeding.
For a full list of side effects and reactions, check the official prescribing information.
Remember, Amovig or Aimoving are just misspellings of Aimovig. They are not different drugs.
Reviews
There are no reviews yet.